Fibrotest limitations in the management of hepatitis C;Les limites du fibrotest dans la prise en charge de l'hépatite C

Gastroenterologie Clinique et Biologique

Volumn 30, Issue 1, 2006, Pages 117-120

  Halfon, Philippe ^a  

^a Laboratoire Alphabio   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC ACCURACY; DISEASE PREDISPOSITION; EDITORIAL; HEPATITIS C; HUMAN; LABORATORY TEST; LIVER BIOPSY; PATHOGENESIS; QUANTITATIVE ANALYSIS;

EID: 32144433200     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(06)73125-6     Document Type: Editorial

References (20)

1. Halfon P, Bourlière M, Deydier R, Botta-Fridlund D, Renou C, Tran A, et al. Independant prospective multicenter validation of biochemical markers (Fibrotest-Actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C. Am J Gastroenterol 2006 (in press).
2. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-50.
3. EASL. International conference on liver biopsy in diagnosis and management of liver diseases. Turin 14-15 June 2004 (Italy). J Hepatol (in press).
4. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000;32:477-81.
5. Castera L, Negre I, Samii K, Buffet C. Pain experienced during percutaneous liver biopsy. Hepatology 1999;30:1529-30.
6. Munteanu M, Messous D, Thabut D, Imbert-Bismut F, Jouys M, Massard I, et al. Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest). Comp Hepatol 2004;3:3.
7. Imbert-Bismut F, Messous D, Thibaut V, Myers RB, Piton A, Thabut D, et al. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. Clin Chem Lab Med 2004;42:323-33.
8. Halfon P, Imbert-Bismut F, Messous D, Antoniotti G, Benchetrit D, Cart-Lamy P, et al. A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease. Comp Hepatol 2002;1:3.
9. Rosenthal-Allieri MA, Peritore ML, Tran A, Halfon P, Benzaken S, Bernard A. Analytical variability of the Fibrotest proteins. Clin Biochem 2005;38:473-8.
10. Imbert-Bismut F, Messous D, Raoult A, Poynard T, Bertrand JJ, Marie PA, et al. Results transferability on RXL, ARX, X-Pand, BN2 (Dade Behring) and modular DP (Roche Diagnostics) analysers: application to component assays of fibrotest and Actitest]. Ann Biol Clin (Paris) 2005;63:305-13.
11. Poynard T, Munteanu M, Imbert-Bismut F, Charlotte F, Thabut D, Le Calvez S, et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004;50:1344-55.
12. Varaut A, Fontaine H, Serpaggi I, Verkarre V, Vallet-Pichard A, Nalpas B, et al. Diagnostic accuracy of the fibrotest in hemodialysis and renal transplant patients with chronic hepatitis C virus. Transplantation 2005;80:1550-5.
13. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38:1449-57.
14. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002;97:2614-8.
15. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003;39:239-44.
16. Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers RP, Thabut D, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (Acti-Test) in patients with chronic hepatitis C. Comp Hepatol 2004;3:8.
17. Naveau S, Raynard B, Ratziu V, Abella A, Imbert-Bismut F, Messous D, et al. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol 2005; 3:167-74.
18. Poynard T, Zoulim F, Ratziu V, Degos F, Imbert-Bismut F, Deny P, et al. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol 2005;100:1970-80.
19. Myers RP, Tainturier MH, Ratziu V, Piton A, Thibault V, Imbert-Bismut F, et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 2003; 39:222-30.
20. Bourlière M, Pénaranda G, Renou C, Botta-Fridlund D, Tran A, Portal I, et al. Validation and Comparison of Indexes for Fibrosis and Cirrhosis Prediction in Chronic Hepatitis C Patients. J Viral Hepat 2006 (In press).